Earlier this month, US President Joe Biden shocked the pharmaceutical industry with his declared support for an intellectual property waiver for COVID-19 vaccines.
In this special podcast, reporter Charlotte Kilpatrick moderates a debate between Komal Kalha, lead for IP and trade policy at the International Federation of Pharmaceutical Manufacturers & Associations; James Love, director of Knowledge Ecology International; and Gordon Harris, partner at Gowling WLG.
In this heated debate, guests discuss the flexibilities of the TRIPS Agreement, know-how gaps, and whether the waiver – if implemented – could undermine incentives for future pharmaceutical research.
To listen to the 30-minute debate, click the link below.
![1200_17th_images_071812[1] 3.jpg](https://static.legalbenchmarkinggroup.com/dims4/default/403fef9/2147483647/strip/true/crop/3328x1874+0+172/resize/293x165!/quality/90/?url=https%3A%2F%2Fk4-prod-legal.s3.eu-west-1.amazonaws.com%2Fbrightspot%2Fae%2Fda%2F3bb43c034f46989edd34a5c00e5f%2F1200-17th-images-0718121-3.jpg)
